search
Back to results

Impact of Silicon-based Formulations on Wound Healing of Laser-induced Microscopic Skin Lesions (SPASM11)

Primary Purpose

Wound Healing

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Stratacel
Stratamed
Sponsored by
Stratpharma AG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Wound Healing

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy adult volunteers age ≥18 years to 50 years Subjects must be willing and able to participate as required by the protocol. Subjects must be willing and able to provide written informed consent. Exclusion Criteria: Evidence of any relevant skin or systemic disease (for example diabetes mellitus, cardiovascular disease, hypertension, chronic or acute skin disease) possibly affecting the wound healing of the test site. Any skin alteration (for example tattoo or scar) on the test site. Test sites with terminal hairs Pregnancy or breastfeeding. History of hypertrophic scars or keloid formation or a similar abnormal wound healing. Intake of any drug which in the evaluation of the investigator may interfere with the interpretation of trial results or are known to cause clinically relevant interferences. Body Mass Index (BMI) > 36 kg/m². Have any other condition (including drug abuse, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, precludes the patient from following and completing the protocol.

Sites / Locations

  • Hôpitaux universitaires de Genève

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Experimental

Arm Label

Control

Formulation 1

Formulation 2

Arm Description

Outcomes

Primary Outcome Measures

Measurement of erythema severity via erythema index with and without silicon-based formulations.
Erythema severity is measured using the erythema index (EI). EI will be evaluated by a Mexameter by means of duplicate measurements per skin area in arbitrary units.

Secondary Outcome Measures

Time needed for the scab to fall off
Time needed for the scab to fall off will be evaluated through the study of photo documentation conducted thorough the experiment. To obtain the best possible image of the microscopic treatment zones, a DermLite DL4 dermatoscope will be used. The dermatoscope is a non-invasive device, frequently used in dermatology, which allows a better observation of the skin surface by magnifying it.
Volume of microscopic treatment zones (MTZs) and recovery time
Volume of the MTZs and time to recovery will be evaluated using confocal microscopy. Either by using RCM or LC-OCT (both non-invasive), a minimum of 3 MTZs per region will be evaluated. MTZs will also be evaluated following the classical protocol of biopsy fullowed by H&E staining.

Full Information

First Posted
November 1, 2022
Last Updated
September 4, 2023
Sponsor
Stratpharma AG
Collaborators
University Hospital, Geneva
search

1. Study Identification

Unique Protocol Identification Number
NCT05614557
Brief Title
Impact of Silicon-based Formulations on Wound Healing of Laser-induced Microscopic Skin Lesions
Acronym
SPASM11
Official Title
Impact of Silicon-based Formulations on Wound Healing of Laser-induced Microscopic Skin Lesions
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
March 21, 2023 (Actual)
Primary Completion Date
August 31, 2023 (Actual)
Study Completion Date
August 31, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Stratpharma AG
Collaborators
University Hospital, Geneva

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Delayed wound healing is considered a health problem with devastating consequences for patients, healthcare systems, and societies. Over the past 20 years, many other groups, as well as ourselves, have evaluated various alternatives to improve wound healing. Despite this, the scientific evidence demonstrating the efficacy of recently developed treatments is often limited. Stratacel® and Stratamed® are two gels approved by Swissmedic and the FDA for use in improving wound healing. To this end, the efficacy of these formulations has been visually tested by a physician or by patients. Using the most advanced medical technologies (confocal microscopy and LCOCT), this study aims to investigate the effect of these formulations on the healing of human skin. For this research, a total of 20 volunteers will be included in this study. Volunteers will have up to 7 follow-up appointments over 21 days. Each appointment will last approximately 30 minutes and will be used to perform external measurements of skin healing. All volunteers will use the same formulations (Stratacel® and Stratamed®) with the only difference between volunteers being the anatomical area of application of the formulation. This will be determined by chance. The active participation of the participant is requested for the application of the formulations on the skin twice a day during the trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wound Healing

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Title
Formulation 1
Arm Type
Experimental
Arm Title
Formulation 2
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Stratacel
Intervention Description
Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
Intervention Type
Device
Intervention Name(s)
Stratamed
Intervention Description
Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
Primary Outcome Measure Information:
Title
Measurement of erythema severity via erythema index with and without silicon-based formulations.
Description
Erythema severity is measured using the erythema index (EI). EI will be evaluated by a Mexameter by means of duplicate measurements per skin area in arbitrary units.
Time Frame
21+-2 days maximum
Secondary Outcome Measure Information:
Title
Time needed for the scab to fall off
Description
Time needed for the scab to fall off will be evaluated through the study of photo documentation conducted thorough the experiment. To obtain the best possible image of the microscopic treatment zones, a DermLite DL4 dermatoscope will be used. The dermatoscope is a non-invasive device, frequently used in dermatology, which allows a better observation of the skin surface by magnifying it.
Time Frame
21+-2 days maximum
Title
Volume of microscopic treatment zones (MTZs) and recovery time
Description
Volume of the MTZs and time to recovery will be evaluated using confocal microscopy. Either by using RCM or LC-OCT (both non-invasive), a minimum of 3 MTZs per region will be evaluated. MTZs will also be evaluated following the classical protocol of biopsy fullowed by H&E staining.
Time Frame
21+-2 days maximum

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy adult volunteers age ≥18 years to 50 years Subjects must be willing and able to participate as required by the protocol. Subjects must be willing and able to provide written informed consent. Exclusion Criteria: Evidence of any relevant skin or systemic disease (for example diabetes mellitus, cardiovascular disease, hypertension, chronic or acute skin disease) possibly affecting the wound healing of the test site. Any skin alteration (for example tattoo or scar) on the test site. Test sites with terminal hairs Pregnancy or breastfeeding. History of hypertrophic scars or keloid formation or a similar abnormal wound healing. Intake of any drug which in the evaluation of the investigator may interfere with the interpretation of trial results or are known to cause clinically relevant interferences. Body Mass Index (BMI) > 36 kg/m². Have any other condition (including drug abuse, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, precludes the patient from following and completing the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans J. Laubauch, Dr. med.
Organizational Affiliation
Hôpitaux universitaires de Genève
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpitaux universitaires de Genève
City
Geneva
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16392146
Citation
Laubach HJ, Tannous Z, Anderson RR, Manstein D. Skin responses to fractional photothermolysis. Lasers Surg Med. 2006 Feb;38(2):142-9. doi: 10.1002/lsm.20254.
Results Reference
background
PubMed Identifier
23346665
Citation
Sandhofer M, Schauer P. The safety, efficacy, and tolerability of a novel silicone gel dressing following dermatological surgery. Skinmed. 2012 Nov-Dec;10(6):S1-7.
Results Reference
background
PubMed Identifier
24267314
Citation
Monk EC, Benedetto EA, Benedetto AV. Successful treatment of nonhealing scalp wounds using a silicone gel. Dermatol Surg. 2014 Jan;40(1):76-9. doi: 10.1111/dsu.12366. Epub 2013 Nov 25. No abstract available.
Results Reference
background
PubMed Identifier
33276114
Citation
Abdlaty R, Hayward J, Farrell T, Fang Q. Skin erythema and pigmentation: a review of optical assessment techniques. Photodiagnosis Photodyn Ther. 2021 Mar;33:102127. doi: 10.1016/j.pdpdt.2020.102127. Epub 2020 Dec 1.
Results Reference
background
PubMed Identifier
31520439
Citation
Garbarino F, Migliorati S, Farnetani F, De Pace B, Ciardo S, Manfredini M, Reggiani Bonetti L, Kaleci S, Chester J, Pellacani G. Nodular skin lesions: correlation of reflectance confocal microscopy and optical coherence tomography features. J Eur Acad Dermatol Venereol. 2020 Jan;34(1):101-111. doi: 10.1111/jdv.15953. Epub 2019 Oct 15.
Results Reference
background

Learn more about this trial

Impact of Silicon-based Formulations on Wound Healing of Laser-induced Microscopic Skin Lesions

We'll reach out to this number within 24 hrs